Products

Products

Prognostic test for liver cancer

The OncoHePaTest® is the world’s first commercialized prognostic test in liver cancer which is to predict overall survival and recurrence to optimize the surgical treatment outcomes.
Clinical validated safety and effectiveness of OncoHePaTest® has received regulatory approved New Health Technology by the Korea Ministry of Health & Welfare (Oct 2010).
It’s a worldwide patented and multi-center validated technology.
Comparing to the conventional treatment for HCC patients, OncoHePaTest® optimized the outcome of treatment(resection, TACE, PEI, RFA) according to patients’ genomic features.

  • 1 Globally the first clinical validated and commercialized prognostic test for liver cancer
  • 2 Legally approved genetic test certified as New Health Technology by Ministry of Health & Welfare (Republic of Korea)
  • 3 The technology development and validation is based on the globally largest HCC cohort
  • 4 Global top-tier medical institutions joint the multi-center clinical validation (Ajou University hospital, Hanyang university medical center, Samsung Medical Center, Keimyung university dongsan medical center, Asan medical center, Korea university Anam hospital, Korea university Guro hospital, Korea university Ansan hospital)
  • 5 Best performance among commercialized genetic tests worldwide